Non-steroidal Glucocorticoid Receptor Modulators for Selective Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and immune-related diseases, such as rheumatoid arthritis and asthma, face limitations due to side effects from systemic glucocorticoid use, and there is a need for compounds that can modulate glucocorticoid receptor, AP-1, and NF-κB activity to address both inflammatory suppression and metabolic disorders.
Innovation Solution
Development of new non-steroidal compounds with a specific structure that modulate glucocorticoid receptor, AP-1, and NF-κB activity, allowing for targeted treatment of inflammatory and immune-related diseases while minimizing side effects by selectively inhibiting or activating transcriptional pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic glucocorticoids are used to treat inflammatory diseases, then anti-inflammatory efficacy is improved, but side effects increase
Solution Approach 1:
The invention segments the glucocorticoid receptor's transcriptional activity into distinct pathways (AP-1 regulation and NF-κB regulation) and develops compounds that can selectively modulate one pathway without affecting the other. This allows for targeted anti-inflammatory action while avoiding side effects associated with broad glucocorticoid activity.
Solution Approach 2:
The patent applies local quality by creating compounds with selective affinity for specific transcriptional pathways. The compounds exhibit different modulatory properties depending on the target pathway - some compounds preferentially regulate AP-1 while others preferentially regulate NF-κB, enabling localized therapeutic action at the molecular level.
2Reliability
If glucocorticoid receptor activity is modulated to treat inflammatory diseases, then inflammation is suppressed, but metabolic disorders may occur
Solution Approach 1:
The invention separates the glucocorticoid receptor's anti-inflammatory function from its metabolic effects by selectively modulating transcriptional pathways. By targeting specific pathways (AP-1 or NF-κB) rather than global glucocorticoid activity, the compounds suppress inflammation while sparing metabolic pathways that would otherwise be disrupted.
Solution Approach 2:
The patent introduces selective modulator compounds as intermediaries between the glucocorticoid receptor and transcriptional pathways. These compounds act as selective mediators that can activate or inhibit specific transcriptional outputs (AP-1 or NF-κB) without triggering the broad metabolic effects associated with traditional glucocorticoid activation.
3Object-affected harmful factors
If selective modulation of transcriptional pathways is achieved, then side effects are reduced, but compound specificity and complexity increase
Solution Approach 1:
The patent achieves selective modulation by changing molecular parameters of the compounds - specifically, by modifying structural features that determine binding affinity and selectivity for different transcriptional pathways. By adjusting these parameters, compounds can be tuned to preferentially regulate AP-1 or NF-κB while maintaining manageable structural complexity.
Data Source
AI summary
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.